WEED Adds 30 Year Genomics Veteran to Board of Directors
Complete the form below and we will email you a PDF version of "WEED Adds 30 Year Genomics Veteran to Board of Directors "
WEED is pleased to announce the appointment of Dr. Patrick E. Williams to the Board of Directors of the company as of January, 2018.
Dr. Williams is the President and Chief Science Officer of Sangre AT, a wholly-owned subsidiary of WEED. In that capacity, Dr. Williams oversees Sangre's Cannabis Genomic Study, including genomic sequencing, genetics-based breeding, plant tissue culture, and plant biochemistry, utilizing some of the most advanced sequencing and analytical technologies and proprietary bioinformatics data systems available. In addition to serving on the company's Board of Directors, Dr. Williams will oversee genomic studies and clinical trials for the company worldwide.
"We are very pleased to welcome Dr. Williams to the WEED Board. His expertise in plant genetics and molecular biology and his guidance in managing projects are tremendously valuable to WEED's current genomic study, as well as our future plans," stated Glenn E. Martin, President and CEO of WEED.
Dr. Williams stated, "I am excited at the opportunity to join the WEED Board. WEED is dedicated to the medical cannabis industry and is focused on developing the required scientifically-valid and evidence-based cannabis strains for the production of disease-specific medicines."
Dr. Williams has more than 30 years of experience in the development of new analytical methods and instruments for bio-molecular testing. Dr. Williams served on the National Scientific Review Board for the Human Genome Project, provided technical leadership as the branch chief of the Armed Forces DNA Technology Development Program of the Armed Forces Institute of Pathology at Walter Reed Army Medical Center, Washington, DC, and served on numerous NIH Study Sections on technology development. His responsibilities have included conceptualizing and managing key projects, technology transfers, and collaborative research programs, laboratory process improvement, grant writing, fundraising and budgeting, staffing, managing personnel, identifying outside collaborators, and directing subcontractors. Dr. Williams is focusing his years of experience on understanding the cannabis genome and how it will provide the blueprints for the development of significant medicinal products for the treatment of human disease.